Proteobacteria: A common factor in human diseases

BioMed Research International

Volumn 2017, Issue , 2017, Pages

  Rizzatti, G ^a   Lopetuso, L R ^a   Gibiino, G ^a   Binda, C ^a   Gasbarrini, A ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASES; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; LUNG DISEASE; METABOLIC DISORDER; NONHUMAN; PROTEOBACTERIA; REVIEW; ANIMAL; BACTERIAL INFECTION; COMPLICATION; MICROFLORA; PHYSIOLOGY;

ANIMALS; BACTERIAL INFECTIONS; DISEASE; HUMANS; MICROBIOTA; PROTEOBACTERIA;

EID: 85042357749     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2017/9351507     Document Type: Review

References (81)

1. R. E. Ley, D. A. Peterson, and J. I. Gordon, “Ecological and evolutionary forces shaping microbial diversity in the human intestine,” Cell, vol. 124, no. 4, pp. 837–848, 2006.
2. S. Khanna and P. K. Tosh, “A clinician’s primer on the role of the microbiome in human health and disease,” Mayo Clinic Proceedings, vol. 89, no. 1, pp. 107–114, 2014.
3. S. Dollive, G. L. Peterfreund, S. Sherrill-Mix et al., “A tool kit for quantifying eukaryotic rRNA gene sequences from human microbiome samples,” Genome Biology, p. R60, 2012.
4. M. E. Berg Miller, C. J. Yeoman, N. Chia et al., “Phage-bacteria relationships and CRISPR elements revealed by a metagenomic survey of the rumen microbiome,” Environmental Microbiology, vol. 14, no. 1, pp. 207–227, 2012.
5. L. R. Lopetuso, G. Ianiro, F. Scaldaferri, G. Cammarota, and A. Gasbarrini, “Gut Virome and Inflammatory Bowel Disease,” Inflammatory Bowel Diseases, vol. 22, no. 7, pp. 1708–1712, 2016.
6. J. Qin, R. Li, J. Raes et al., “A human gut microbial gene catalogue established by metagenomic sequencing,” Nature, vol. 464, pp. 59–65, 2010.
7. A. S. Neish, “Microbes in gastrointestinal health and disease,” Gastroenterology, vol. 136, no. 1, pp. 65–80, 2009.
8. A. M. O’Hara and F. Shanahan, “The gut flora as a forgotten organ,” EMBO Reports, vol. 7, no. 7, pp. 688–693, 2006.
9. D. N. Frank, A. L. S. Amand, R. A. Feldman, E. C. Boedeker, N. Harpaz, and N. R. Pace, “Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 104, no. 34, pp. 13780–13785, 2007.
10. J. E. Koenig, A. Spor, N. Scalfone et al., “Succession of microbial consortia in the developing infant gut microbiome,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 108, supplement 1, pp. 4578–4585, 2011.
11. P. A. M. J. Scholtens, R. Oozeer, R. Martin, K. B. Amor, and J. Knol, “The early settlers: Intestinal microbiology in early life,” Annual Review of Food Science and Technology, vol. 3, no. 1, pp. 425–447, 2012.
12. E. Biagi, L. Nylund, M. Candela et al., “Through ageing, and beyond: Gut microbiota and inflammatory status in seniors and centenarians,” PLoS ONE, vol. 5, 2010.
13. F. Bäckhed, R. E. Ley, J. L. Sonnenburg, D. A. Peterson, and J. I. Gordon, “Host-bacterial mutualism in the human intestine,” Science, vol. 307, no. 5717, pp. 1915–1920, 2005.
14. A. Huurre, M. Kalliomäki, S. Rautava, M. Rinne, S. Salminen, and E. Isolauri, “Mode of delivery - Effects on gut microbiota and humoral immunity,” Neonatology, vol. 93, no. 4, pp. 236–240, 2008.
15. M. J. Hill, “Intestinal flora and endogenous vitamin synthesis,” EuropeanJournalofCancerPrevention,vol.6,no.1,pp.S43–S45, 1997.
16. F. Scaldaferri, M. Pizzoferrato, V. Gerardi, L. Lopetuso, and A. Gasbarrini, “The gut barrier: new acquisitions and therapeutic approaches,” Journal of Clinical Gastroenterology, vol. 46, supplement, pp. S12–S17, 2012.
17. E. Stackebrandt, R. G. E. Murray, and H. G. Truper, “Proteobacteria classis nov., a name for the phylogenetic taxon that includes the’purple bacteria and their relatives’,” International Journal of Systematic Bacteriology, vol. 38, no. 3, pp. 321–325, 1988.
18. C. R. Woese, “Bacterial evolution,” Clinical Microbiology Reviews, vol. 51, pp. 221–271, 1987.
19. Human Microbiome Project C, “Structure, function and diversity of the healthy human microbiome,” Nature, vol. 486, pp. 207–214, 2012.
20. L. Brunkwall and M. Orho-Melander, “The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: from current human evidence to future possibilities,” Diabetologia, vol. 60, no. 6, pp. 943–951, 2017.
21. M. J. Khan, K. Gerasimidis, C. A. Edwards, and M. G. Shaikh, “Role of Gut Microbiota in the Aetiology of Obesity: Proposed Mechanisms and Review of the Literature,” Journal of Obesity, vol. 2016, Article ID 7353642, 2016.
22. W. H. W. Tang, T. Kitai, and S. L. Hazen, “Gut microbiota in cardiovascular health and disease,” Circulation Research, vol. 120, no. 7, pp. 1183–1196, 2017.
23. A. Zhu, J. Chen, P. Wu et al. et al., “Cationic Polystyrene Resolves Nonalcoholic Steatohepatitis (NASH), Obesity, and Metabolic Disorders by Promoting Eubiosis of Gut Microbiota and Decreasing Endotoxemia,” Diabetes, 2017.
24. American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 37, supplement 1, pp. S81–S90, 2014.
25. S. M. Lambeth, T. Carson, J. Lowe et al., “Composition, Diversity and Abundance of Gut Microbiome in Prediabetes and Type 2 Diabetes,” Journal of Diabetes and Obesity, vol. 2, pp. 1–7, 2015.
26. G. S. Hotamisligil, “Inflammation and metabolic disorders,” Nature, vol. 444, no. 7121, pp. 860–867, 2006.
27. P. D. Cani, J. Amar, M. A. Iglesias et al., “Metabolic endotoxemia initiates obesity and insulin resistance,” Diabetes, vol. 56, no. 7, pp. 1761–1772, 2007.
28. P. D. Cani, R. Bibiloni, C. Knauf et al., “Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice,” Diabetes, vol. 57, no. 6, pp. 1470–1481, 2008.
29. T. Sen, C. R. Cawthon, B. T. Ihde et al., “Diet-driven microbiota dysbiosis is associated with vagal remodeling and obesity,” Physiology & Behavior, vol. 173, pp. 305–317, 2017.
30. N. Larsen, F. K. Vogensen, F. W. J. van den Berg et al., “Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults,” PLoS ONE, vol. 5, no. 2, Article ID e9085, 2010.
31. J. J. Qin, Y. R. Li, Z. M. Cai et al., “A metagenome-wide association study of gut microbiota in type 2 diabetes,” Nature, vol. 490, no. 7418, pp. 55–60, 2012.
32. N. Fei and L. Zhao, “An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice,” The ISME Journal, vol. 7, no. 4, pp. 880–884, 2013.
33. F. Bäckhed, J. K. Manchester, C. F. Semenkovich, and J. I. Gordon, “Mechanisms underlying the resistance to diet-induced obesity in germ-free mice,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 104, no. 3, pp. 979–984, 2007.
34. S. Rabot, M. Membrez, A. Bruneau et al., “Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism,” The FASEB Journal, vol. 24, no. 12, pp. 4948–4959, 2010.
35. P. J. Turnbaugh, R. E. Ley, M. A. Mahowald, V. Magrini, E. R. Mardis, and J. I. Gordon, “An obesity-associated gut microbiome with increased capacity for energy harvest,” Nature, vol. 444, no. 7122, pp. 1027–1031, 2006.
36. M. Ellekilde, E. Selfjord, C. S. Larsen et al., “Transfer of gut microbiota from lean and obese mice to antibiotic-treated mice,” Scientific Reports, vol. 4, article no. 5922, 2014.
37. A. Vrieze, E. Van Nood, F. Holleman et al., “Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome,” Gastroenterology, vol. 143, no. 4, pp. e913–e917, 2012.
38. S. Michail, M. Lin, M. R. Frey et al., “Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease,” FEMS Microbiology Ecology, vol. 91, no. 2, pp. 1–9, 2015.
39. N. Ren, D. Xing, B. E. Rittmann, L. Zhao, T. Xie, and X. Zhao, “Microbial community structure of ethanol type fermentation in bio-hydrogen production,” Environmental Microbiology, vol. 9, no. 5, pp. 1112–1125, 2007.
40. L. Zhu, S. S. Baker, C. Gill et al., “Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH,” Hepatology, vol. 57, no. 2, pp. 601–609, 2013.
41. S. Kapil, A. Duseja, B. K. Sharma et al., “Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease,” Journal of Gastroenterology and Hepatology, vol. 31, no. 1, pp. 213–221, 2016.
42. A. C. Vaughn, E. M. Cooper, P. M. Dilorenzo et al., “Energy-dense diet triggers changes in gut microbiota, reorganization of gut-brain vagal communication and increases body fat accumulation,” Acta Neurobiologiae Experimentalis, vol. 77, no. 1, pp. 18–30, 2017.
43. C. de Filippo, D. Cavalieri, M. di Paola et al., “Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 107, no. 33, pp. 14691–14696, 2010.
44. J. Amar, C. Lange, G. Payros et al., “Blood microbiota dysbiosis is associated with the onset of cardiovascular events in a large general population: the D.E.S.I.R. study,” PLoS ONE, vol. 8, no. 1, Article ID e54461, 2013.
45. G. K. Hansson, “Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease,” The New England Journal of Medicine, vol. 352, no. 16, pp. 1626–1695, 2005.
46. S. E. Epstein, J. Zhu, M. S. Burnett, Y. F. Zhou, G. Vercellotti, and D. Hajjar, “Infection and atherosclerosis: Potential roles of pathogen burden and molecular mimicry,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 6, pp. 1417–1420, 2000.
47. O. Koren, A. Spor, J. Felin et al., “Human oral, gut, and plaque microbiota in patients with atherosclerosis,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 108, no. 1, pp. 4592–4598, 2011.
48. J. B. Grigg and G. F. Sonnenberg, “Host-microbiota interactions shape local and systemic inflammatory diseases,” The Journal of Immunology, vol. 198, no. 2, pp. 564–571, 2017.
49. A. E. Slingerland, Z. Schwabkey, D. H. Wiesnoski, and R. R. Jenq, “Clinical Evidence for the Microbiome in Inflammatory Diseases,” Frontiers in Immunology, vol. 8, no. 400, 2017.
50. N.-R. Shin, T. W. Whon, and J.-W. Bae, “Proteobacteria: microbial signature of dysbiosis in gut microbiota,” Trends in Biotechnology, vol. 33, no. 9, pp. 496–503, 2015.
51. J. Mirpuri, M. Raetz, C. R. Sturge et al., “Proteobacteria-specific IgA regulates maturation of the intestinal microbiota,” Gut Microbes, vol. 5, no. 1, pp. 28–39, 2014.
52. T. Selvanantham, Q. Lin, C. X. Guo et al., “NKT cell-deficient mice harbor an altered microbiota that fuels intestinal inflammation during chemically induced colitis,” The Journal of Immunology, vol. 197, no. 11, pp. 4464–4472, 2016.
53. N. Maharshak, C. D. Packey, M. Ellermann et al., “Altered enteric microbiota ecology in interleukin 10-deficient mice during development and progression of intestinal inflammation,” Gut Microbes, vol. 4, no. 4, pp. 316–324, 2013.
54. F. A. Carvalho, O. Koren, J. K. Goodrich et al., “Transient inability to manage proteobacteria promotes chronic gut inflammation in TLR5-deficient mice,” Cell Host & Microbe, vol. 12, no. 2, pp. 139–152, 2012.
55. D. Langgartner, D. Peterlik, S. Foertsch et al., “Individual differences in stress vulnerability: The role of gut pathobionts in stress-induced colitis,” Brain, Behavior, and Immunity, vol. 64, pp. 23–32, 2016.
56. S. H. Rhee, C. Pothoulakis, and E. A. Mayer, “Principles and clinical implications of the brain–gut–enteric microbiota axis,” Nature Reviews Gastroenterology & Hepatology, vol. 6, no. 5, pp. 306–314, 2009.
57. S. M. Collins, M. Surette, and P. Bercik, “The interplay between the intestinal microbiota and the brain,” Nature Reviews Microbiology, vol. 10, no. 11, pp. 735–742, 2012.
58. J. F. Cryan and T. G. Dinan, “Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour,” Nature Reviews Neuroscience, vol. 13, no. 10, pp. 701–712, 2012.
59. B. Khor, A. Gardet, and R. J. Xavier, “Genetics and pathogenesis of inflammatory bowel disease,” Nature, vol. 474, no. 7351, pp. 307–317, 2011.
60. R. B. Sartor, “Microbial influences in inflammatory bowel diseases,” Gastroenterology, vol. 134, no. 2, pp. 577–594, 2008.
61. D. A. Peterson, N. P. McNulty, J. L. Guruge, and J. I. Gordon, “IgA response to symbiotic bacteria as a mediator of gut homeostasis,” Cell Host & Microbe, vol. 2, no. 5, pp. 328–339, 2007.
62. A. Rehman, P. Lepage, A. Nolte, S. Hellmig, S. Schreiber, and S. J. Ott, “Transcriptional activity of the dominant gut mucosal microbiota in chronic inflammatory bowel disease patients,” Journal of Medical Microbiology, vol. 59, part 9, pp. 1114–1122, 2010.
63. U. Gophna, K. Sommerfeld, S. Gophna, W. F. Doolittle, and S. J. O. Veldhuyzen Van Zanten, “Differences between tissue-associated intestinal microfloras of patients with Crohn’s disease and ulcerative colitis,” Journal of Clinical Microbiology, vol. 44, no. 11, pp. 4136–4141, 2006.
64. L. Rigottier-Gois, “Dysbiosis in inflammatory bowel diseases: the oxygen hypothesis,” The ISME Journal, vol. 7, no. 7, pp. 1256–1261, 2013.
65. F. Rivera-Chávez, C. A. Lopez, and A. J. Bäumler, “Oxygen as a driver of gut dysbiosis,” Free Radical Biology & Medicine, vol. 105, pp. 93–101, 2017.
66. E. R. Hughes, M. G. Winter, B. A. Duerkop et al., “Microbial Respiration and Formate Oxidation as Metabolic Signatures of Inflammation-Associated Dysbiosis,” Cell Host & Microbe, vol. 21, no. 2, pp. 208–219, 2017.
67. Y. Litvak, M. X. Byndloss, R. M. Tsolis, and A. J. Bäumler, “Dysbiotic Proteobacteria expansion: a microbial signature of epithelial dysfunction,” Current Opinion in Microbiology, vol. 39, pp. 1–6, 2017.
68. S. E. Winter, M. G. Winter, M. N. Xavier et al., “Host-derived nitrate boosts growth of E. coli in the inflamed gut,” Science, vol. 339, no. 6120, pp. 708–711, 2013.
69. M. X. Byndloss, E. E. Olsan, F. Rivera-Chávez et al., “Microbiota-activated PPAR- signaling inhibits dysbiotic Enterobacteriaceae expansion,” Science, vol. 357, no. 6351, pp. 570–575, 2017.
70. J. Boudeau, A.-L. Glasser, E. Masseret, B. Joly, and A. Darfeuille-Michaud, “Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn’s disease,” Infection and Immunity, vol. 67, no. 9, pp. 4499–4509, 1999.
71. N. Barnich, J. Denizot, and A. Darfeuille-Michaud, “E. coli-mediated gut inflammation in genetically predisposed Crohn’s disease patients,” Pathologie Biologie, vol. 61, no. 5, pp. e65–e69, 2013.
72. A. Darfeuille-Michaud, J. Boudeau, P. Bulois et al., “High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease,” Gastroenterology, vol. 127, no. 2, pp. 412–421, 2004.
73. B. Willing, J. Halfvarson, J. Dicksved et al., “Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn’s disease,” Inflammatory Bowel Diseases, vol. 15, no. 5, pp. 653–660, 2009.
74. D. Knights, M. S. Silverberg, R. K. Weersma et al., “Complex host genetics influence the microbiome in inflammatory bowel disease,” Genome Medicine, vol. 6, article 107, 2014.
75. S. D. Shukla, K. F. Budden, R. Neal, and P. M. Hansbro, “Microbiome effects on immunity, health and disease in the lung,” Clinical & Translational Immunology, vol. 6, no. 3, p. e133, 2017.
76. M.-S. Ong, D. T. Umetsu, and K. D. Mandl, “Consequences of antibiotics and infections in infancy: Bugs, drugs, and wheezing,” Annals of Allergy, Asthma & Immunology, vol. 112, no. 5, pp. 441–e1, 2014.
77. M. Hilty, C. Burke, H. Pedro et al., “Disordered microbial communities in asthmatic airways,” PLoS ONE, vol. 5, no. 1, Article ID e8578, 2010.
78. P. R. Marri, D. A. Stern, A. L. Wright, D. Billheimer, and F. D. Martinez, “Asthma-associated differences in microbial composition of induced sputum,” The Journal of Allergy and Clinical Immunology, vol. 131, no. 2, pp. 346.e3–352.e3, 2013.
79. L. Biedermann, J. Zeitz, J. Mwinyi et al., “Smoking Cessation Induces Profound Changes in the Composition of the Intestinal Microbiota in Humans,” PLoS ONE, vol. 8, no. 3, Article ID e59260, 2013.
80. A. A. Pragman, H. B. Kim, C. S. Reilly, C. Wendt, and R. E. Isaacson, “The Lung Microbiome in Moderate and Severe Chronic Obstructive Pulmonary Disease,” PLoS ONE, vol. 7, no. 10, Article ID e47305, 2012.
81. Z. Wang, M. Bafadhel, K. Haldar et al., “Lung microbiome dynamics in COPD exacerbations,” European Respiratory Journal, vol. 47, no. 4, pp. 1082–1092, 2016.